Unichem Lab gets EIR from USFDA for Ghaziabad formulation unit

By: |
New Delhi | Published: June 7, 2017 12:22:00 PM

Drug firm Unichem Laboratories today said it has received an establishment inspection report from the US health regulator for its formulation manufacturing facility in Ghaziabad.

Drug, Drug firm, Unichem Laboratories, USFDA, Ghaziabad formulation unit, Unichem Lab, US health regulator, formulation manufacturing facilityThe USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed. (Reuters)

Drug firm Unichem Laboratories today said it has received an establishment inspection report from the US health regulator for its formulation manufacturing facility in Ghaziabad. “The company’s formulations manufacturing facility at Ghaziabad has received an establishment inspection report (EIR) from the USFDA. This receipt indicates the successful closure of the inspection and the queries raised during the audit (Form 483),” Unichem Laboratories said in a BSE filing.

Also Watch:

It further said: “The inspection has now been closed by the USFDA. The inspection was carried out between February 24, 2017 and March 3, 2017.” The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed. The stock of company was trading at Rs 249.50 apiece, up 1.07 per cent from its previous close on the BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Moody’s downgrades Anil Ambani led Reliance Communications
2Major airports across India set for Rs 2,400 cr makeover in FY18; Rs 400 cr set aside for UDAN
3Robert Bosch Venture Capital plans India presence